Novartis once once more saw its revenues decline between October and the end of December 2022, following suffering from currency effects in the previous quarter. Turnover fell by 4% to 12.69 billion dollars (11.6 billion francs). Profitability, on the other hand, followed an opposite curve and shareholders can count on a dividend for 2022 of 3.20 francs, once morest 3.10 francs for 2021.
Both the core business in innovative medicines and the generics and biosimilars subsidiary in the process of becoming autonomous suffered from the effects of exchange rates. The contribution of Innovative Medicines melted by 3.2% to 10.36 billion, that of Sandoz by 7.7% to 2.33 billion, details a report released on Wednesday.
Net profit up
Adjusted operating surplus (Ebit) fell by 5.5% to 4.03 billion and net profit by 3.7% to 3.25 billion.
Read also: Data, the Achilles heel of Swiss pharma
Revenues are mixed but profitability is much better than expected by the analysts consulted by AWP.
Development follows
Read also: How to preserve Swiss prosperity?
